- Home
- PLYA vs SPRY Comparison
PLYA vs SPRY Comparison
Compare PLYA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLYA
- SPRY
- Stock Information
- Founded
- PLYA 2006
- SPRY 2015
- Country
- PLYA Netherlands
- SPRY United States
- Employees
- PLYA N/A
- SPRY 24
- Industry
- PLYA Hotels/Resorts
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- PLYA Consumer Discretionary
- SPRY Health Care
- Exchange
- PLYA Nasdaq
- SPRY Nasdaq
- Market Cap
- PLYA 1.2B
- SPRY 1.1B
- IPO Year
- PLYA N/A
- SPRY N/A
- Fundamental
- Price
- PLYA $12.25
- SPRY $11.41
- Analyst Decision
- PLYA Strong Buy
- SPRY Strong Buy
- Analyst Count
- PLYA 5
- SPRY 4
- Target Price
- PLYA $12.00
- SPRY $24.00
- AVG Volume (30 Days)
- PLYA 1.3M
- SPRY 1.1M
- Earning Date
- PLYA 11-06-2024
- SPRY 11-13-2024
- Dividend Yield
- PLYA N/A
- SPRY N/A
- EPS Growth
- PLYA 106.66
- SPRY N/A
- EPS
- PLYA 0.49
- SPRY N/A
- Revenue
- PLYA $949,669,000.00
- SPRY $2,568,000.00
- Revenue This Year
- PLYA N/A
- SPRY $66,750.00
- Revenue Next Year
- PLYA $3.31
- SPRY $508.63
- P/E Ratio
- PLYA $25.10
- SPRY N/A
- Revenue Growth
- PLYA 0.71
- SPRY 8460.00
- 52 Week Low
- PLYA $6.95
- SPRY $5.19
- 52 Week High
- PLYA $12.70
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- PLYA 77.99
- SPRY 35.74
- Support Level
- PLYA $9.38
- SPRY $10.80
- Resistance Level
- PLYA $12.70
- SPRY $14.50
- Average True Range (ATR)
- PLYA 0.39
- SPRY 0.77
- MACD
- PLYA 0.17
- SPRY -0.12
- Stochastic Oscillator
- PLYA 86.45
- SPRY 20.20
About PLYA Playa Hotels & Resorts N.V.
Playa Hotels & Resorts NV acts as an owner, operator, and developer of all-inclusive resorts in prime beachfront locations in popular vacation destinations in Mexico and the Caribbean. The company's segments are Yucatan Peninsula, Pacific Coast, Dominican Republic, and Jamaica. It generates a majority of its revenue from the Yucatan Peninsula segment. Its brand profile consists of HYATT ZIVA, HYATT ZILARA, Hilton, JEWEL RESORTS, and others.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.